Northwest Biotherapeutics Files Q1 2025 10-Q
Ticker: NWBO · Form: 10-Q · Filed: 2025-05-15T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
NWBO Q1 2025 10-Q filed. Financials and ops update.
AI Summary
Northwest Biotherapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with a quarterly update on Northwest Biotherapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the biopharmaceutical sector.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often carry higher risk due to the nature of drug development, regulatory hurdles, and market competition.
Key Numbers
- $550,000 — Derivative Gain/Loss (Related Party Transaction)
- $736,000 — Derivative Gain/Loss (Related Party Transaction)
Key Players & Entities
- NORTHWEST BIOTHERAPEUTICS INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250515 (date) — Filing Date
- BETHESDA, MD (location) — Business Address
- 001-35737 (other) — SEC File Number
FAQ
What was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing was March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 15, 2025.
What is the company's primary business address?
The company's business address is 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814.
What is the company's SEC file number?
The company's SEC file number is 001-35737.
What are some of the inputs used for fair value measurements of warrant liability?
Inputs mentioned for fair value measurements of warrant liability include risk-free interest rate, price volatility, expected term, and expected dividend rate.
From the Filing
0001410578-25-001333.txt : 20250515 0001410578-25-001333.hdr.sgml : 20250515 20250515162312 ACCESSION NUMBER: 0001410578-25-001333 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 25953779 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 10-Q 1 nwbo-20250331x10q.htm 10-Q NORTHWEST BIOTHERAPEUTICS INC_March 31, 2025 http://www.nwbio.com/20250331#ResearchAndOtherRevenueMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0001072379 --12-31 2025 Q1 false http://fasb.org/us-gaap/2024#RelatedPartyMember NORTHWEST BIOTHERAPEUTICS INC NONE http://www.nwbio.com/20250331#ResearchAndOtherRevenueMember 0 0 0 0 0 http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet P2Y http://fasb.org/us-gaap/2024#RelatedPartyMember 550000 736000 http://fasb.org/us-gaap/2024#RelatedPartyMember 0.04 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExercisePriceMember 2025-03-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2025-03-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2024-12-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2024-03-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2023-12-31 0001072379 us-gaap:RetainedEarningsMember 2025-03-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001072379 nwbo:SubscriptionReceivableMember 2025-03-31 0001072379 us-gaap:RetainedEarningsMember 2024-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001072379 nwbo:SubscriptionReceivableMember 2024-12-31 0001072379 us-gaap:RetainedEarningsMember 2024-03-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001072379 nwbo:SubscriptionReceivableMember 2024-03-31 0001072379 us-gaap:RetainedEarningsMember 2023-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001072379 nwbo:SubscriptionReceivableMember 2023-1